June 23, 2015

Loma Lux Laboratories has unveiled new packaging that spotlights its patented, natural mineral technology formulations that, according to the company, have been clinically validated and dermatologist-developed to relieve the skin inflammatory disorders of acne, eczema and psoriasis.

June 15, 2015

Such chronic skin conditions as psoriasis and eczema have taken an anti-itch category known for its summertime seasonal sales spikes — because of such acute needs as poison ivy and bug bites — and have made it a year-round destination category.

June 15, 2015

Cosmederm Bioscience’s TriCalm OTC itch-relief solution was recognized in May by the journal Clinical, Cosmetic and Investigational Dermatology,, which published a study finding that Cosmederm’s solution was superior to diphenhydramine 2% and hydrocortisone 1%.

February 24, 2015

Shire on Tuesday acquired Meritage, which includes the phase 3-ready compound Oral Budesonide Suspension for the treatment of adolescents and adults with eosinophilic esophagitis.

January 7, 2015

New packaging formats, consumer interest in therapeutic body care and a long, cold 2013-2014 winter in much of the United States helped fuel sales in the body-, hand- and foot-care category — a category that, according to research firm Mintel, experienced virtually no sales growth between 2009 and 2011.

December 10, 2014

Mylan on Wednesday launched its celecoxib capsules in 50-, 100-, 200- and 400-mg dosage strengths. The drug is one of the first available generic versions of Celebrex capsules from Pfizer.

December 2, 2014

Ranbaxy Laboratories on Monday announced the launch of Infimab (BOW015), the first Remicade (Infliximab) biosimilar in India. The product was launched at the Indian Rheumatology Association Conference in Chandigarh.

November 17, 2014

Genzyme, a Sanofi company, on Friday announced that the Food and Drug Administration approved Lemtrada (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis. 

October 9, 2014

Salix Pharmaceuticals on Thursday announced that the Food and Drug Administration granted final approval for the company's Uceris (budesonide) rectal foam for patients with mild-to-moderate distal ulcerative colitis. 

September 25, 2014

AbbVie on Thursday announced that the Food and Drug Administration approved Humira (adalimumab) as a treatment for pediatric Crohn's disease patients ages 6 years and older when other treatments haven't worked well enough.

 

June 25, 2014

Quest Products has announced the national launch of its ProVent Eczema and Psoriasis Spray, a spray formulated to help minimize the appearance of skin conditions often associated with eczema and psoriasis.

June 11, 2014

Advanced Care Scripts, a division of Omnicare Specialty Care Group, on Wednesday announced that it has been added to the limited-distribution network for Celgene's Otezla (apremilast).

June 9, 2014

Strides Arcolab last week received approval from the Food and Drug Administration for methoxsalen capsules USP, 10-mg (soft gelatin capsules).

June 2, 2014

Mylan announced on Monday that it has entered into a settlement and license agreement with Pfizer relating to Mylan's abbreviated new drug application filed with the U.S. Food and Drug Administration for celecoxib capsules in 50-mg, 100-mg, 200-mg and 400-mg strengths.

May 21, 2014

Takeda Pharmaceutical on Tuesday announced that the Food and Drug Administration simultaneously approved a new biologic therapy, Entyvio (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease.

April 3, 2014

Axium Healthcare Pharmacy announced that it will begin to dispense Otezla, the new oral therapy for the treatment of adults with active psoriatic arthritis.

March 31, 2014

Just days after the Food and Drug Administration approved Otezla, a new oral therapy to treat active psoriatic arthritis in adult patients, Avella Specialty Pharmacy on Friday announced that it is prepared to begin distributing the drug.

March 24, 2014

Celgene on Friday announced that the Food and Drug Administration has approved Otezla (apremilast), the company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), for the treatment of adult patients with active psoriatic arthritis.

March 13, 2014

TriDerma, a provider in medical strength skin care products, has announced that its Facial Redness Repair and Psoriasis Control Skin Healing Creams are now available in California Target stores.

February 4, 2014

The Pharmaceutical Research and Manufacturers of America on Tuesday announced a partnership with the National Institutes of Health that will help spur drug development, the association stated.

February 4, 2014

Salix Pharmaceuticals announced that the Food and Drug Administration has accepted for filing a new drug application for Budesonide 2 mg Rectal Foam for the induction of remission in patients with active mild to moderate distal ulcerative colitis extending up to 40 cm from the anal verge.

January 15, 2014

A new drug for autoimmune diseases from Antares Pharma that the company calls the first of its kind is now available, the drug maker said Wednesday.

January 14, 2014

An educational program partially conceived by a group focused on lupus research is expected to receive $2 million through a congressional appropriations bill.

January 14, 2014

Drug maker Sandoz has started a late-stage clinical trial of a biotech drug used to treat autoimmune disorders, the company said.